SAS Output

20-AUG-2018 6:10

BREAST ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1007-Breast,Adj,N1,Endocrine+/-Chemo 1 Y 1 Recurrence Score testing 9400 9383 90 0 0 0 0 02/28/2011 408 201
            9383 90 0 0 0 0      
 
    2 Y 2 Chemo and Endocrine Therapy 5000 2547 36 0 0 0 0 02/28/2011    
        3 Endocrine Therapy Alone   2536 38 0 0 0 0      
            5083 74 0 0 0 0      
 
  S1207-Brst,Adj,Endocrine+/-Everolimus 1 Y 1 Blinded drug + Endocrine 1900 833 175 86 37 12 3 09/12/2013 458 222
        2 Blinded drug + Endocrine   842 188 82 38 9 3      
            1675 363 168 75 21 6      
 
  S1222-Brst,Fulv. +/- Ever. +/- Anastr. 1 T 1 Blinded treatment 840 12 0 0 0 0 0 05/15/2014 22 7
        2 Blinded treatment   12 0 0 0 0 0      
        3 Blinded treatment   13 0 0 0 0 0      
            37 0 0 0 0 0      
 
  S1416-Brst, TNBC/BRCA, Cis+/- ABT-888 1 Y 1 Blinded Drug + Cisplatin 333 124 63 14 1 1 0 09/15/2016 267 131
        2 Blinded Drug + Cisplatin   123 64 14 2 2 0      
            247 127 28 3 3 0      
 
  S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab) 1 Y 1 Tissue for PD-L1 testing 1000 293 233 135 68 28 4 01/18/2017 461 209
            293 233 135 68 28 4      
 
    2 Y 2 Observation 1000 124 100 58 28 8 1 01/18/2017    
        3 MK-3475 (Pembrolizumab)   121 94 56 30 9 3      
            245 194 114 58 17 4      
 
Yes A011106-Breast, Neoadj, ALTERNATE study 1 E Total Registrations   74 31 21 17 10 4 04/29/2014   122
            74 31 21 17 10 4      
 
  E1Z11-Brst,Genetic Predictors of AIMSS 1 E Total Registrations   153 10 4 3 2 1 08/13/2013   51
            153 10 4 3 2 1      
 
  NRGBR005-Br, Stg II&IIIA, Post NAdj Chemo Br Conserv 1 E Total Registrations   1 1 1 1 0 0 06/22/2018 3 6
            1 1 1 1 0 0      
 
No A011401-Breast, adj, Stage II/III HER2-, weight loss 1 E Total Registrations   170 103 59 33 10 4 10/05/2016   244
            170 103 59 33 10 4      
 
    2 E Total Registrations   155 100 58 34 12 4 10/05/2016    
            155 100 58 34 12 4      
 
  A011502-Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo 1 E Total Registrations   50 39 23 9 0 0 03/20/2017 444 230
            50 39 23 9 0 0      
 
  A221405-Breast, ET interruption, Pregnancy Outcomes 1 E Total Registrations   12 10 4 3 1 0 05/08/2017 131 64
            12 10 4 3 1 0      
 
  B51-Breast, Regional Nodal XRT 1 E Total Registrations   29 12 4 4 0 0 06/13/2014   222
            29 12 4 4 0 0      
 
  B55-Brst, Adj Olaparib for BRCA,TNBC 1 E Total Registrations   65 24 13 7 1 0 12/15/2014 450 187
            65 24 13 7 1 0      
 
    2 E Total Registrations   30 12 7 5 2 1 12/15/2014    
            30 12 7 5 2 1      
 
  E2112-Brst,Adv,Exemestane+/-Entinostat 1 E Total Registrations   53 14 7 3 1 0 04/01/2015   164
            53 14 7 3 1 0      
 
  EA1131-Brst, TNBC, Post-op Chemo vs Obs 0 E Total Registrations   18 6 2 0 0 0 11/12/2015   130
            18 6 2 0 0 0      
 
    1 P Total Registrations   11 6 3 0 0 0 11/12/2015    
            11 6 3 0 0 0      
 
  EA1151-Brst, Tomosynthesis Mammographic Screening 1 E Total Registrations   164 164 156 84 20 2 01/30/2018 143 68
            164 164 156 84 20 2      
 
  NRGBR002-Brst, OMBC, II-III, SoC +/- SBRT and/or SA 1 E Total Registrations   1 1 0 0 0 0 09/22/2017 305 137
            1 1 0 0 0 0      
 
  NRGBR003-Brst,Adj,TNBC,AC -> WP +/- Carbo 1 E Total Registrations   59 20 11 3 0 0 10/16/2015   208
            59 20 11 3 0 0